Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SY-5609 by Syros Pharmaceuticals for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
SY-5609 by Syros Pharmaceuticals for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
SY-5609 by Syros Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
SY-5609 by Syros Pharmaceuticals for Solid Tumor: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
SY-5609 by Syros Pharmaceuticals for Metastatic Pancreatic Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData,...
SY-5609 by Syros Pharmaceuticals for Small-Cell Lung Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...
SY-5609 by Syros Pharmaceuticals for Colorectal Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
SY-5609 by Syros Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
SY-5609 by Syros Pharmaceuticals for Metastatic Breast Cancer: Likelihood of Approval
SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Metastatic Breast Cancer. According to GlobalData,...